BBVA:BMEBanco Bilbao Vizcaya Argentaria, S.A. Analysis
Data as of 2026-05-24 - not real-time
$22.37
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
BBVA is trading at $22.37, just above its near‑term support of $20.70 and well below its 52‑week high, indicating limited upside in the short run. The stock shows a bullish technical backdrop – the 20‑day and 50‑day SMAs are tightly aligned, the MACD histogram is positive and the RSI sits near the midpoint at 52.6, suggesting momentum is steady but not overbought. Fundamentally, the forward PE of 9.3 and a trailing PE of 10.6 are well below the industry average of 16.8, while the dividend yield of 4.8% and a payout ratio under 40% point to a solid income profile.
However, the DCF‑derived fair value of roughly $12.2 is far beneath the current market price, flagging a potential valuation gap. Volatility remains elevated at ~38% over the past month, and a beta of 1.46 signals higher sensitivity to market swings. Analyst sentiment is mixed – a recent UBS downgrade to Neutral and a modest consensus “hold” rating, alongside target prices ranging from $20 to $26, underline the uncertainty. In this context, the stock may be best approached as a value‑oriented, dividend‑focused holding with caution around near‑term price corrections.
However, the DCF‑derived fair value of roughly $12.2 is far beneath the current market price, flagging a potential valuation gap. Volatility remains elevated at ~38% over the past month, and a beta of 1.46 signals higher sensitivity to market swings. Analyst sentiment is mixed – a recent UBS downgrade to Neutral and a modest consensus “hold” rating, alongside target prices ranging from $20 to $26, underline the uncertainty. In this context, the stock may be best approached as a value‑oriented, dividend‑focused holding with caution around near‑term price corrections.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above technical support
- Bullish MACD but limited upside versus DCF fair value
- Elevated volatility and high beta
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Attractive dividend yield with sustainable payout
- PE multiples still below peer average
- Analyst target range indicating modest upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Stable earnings and strong ROE around 19%
- Consistent cash generation supporting dividend
- Diversified geographic footprint reducing single‑country exposure
Key Metrics & Analysis
Financial Health
Revenue Growth11.90%
Profit Margin33.12%
P/E Ratio10.6
ROE19.04%
ROA1.37%
P/B Ratio2.0
Op. Cash Flow$5.1B
Industry P/E16.8
Technical Analysis
TrendBullish
RSI52.6
Support$20.70
Resistance$22.78
MA 20$21.94
MA 50$21.93
MA 200$21.43
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$12.18
Target Price$22.52
Upside/Downside0.67%
GradeOvervalued
TypeValue
Dividend Yield4.82%
Risk Assessment
Beta1.46
Volatility38.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.